Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia

被引:49
作者
Ayestaran, A
Lopez, RM
Montoro, JB
Estibalez, A
Pou, L
Julia, A
Lopez, A
Pascual, B
机构
[1] HOSP GEN VALLE HEBRON,SERV FARM,BARCELONA,SPAIN
[2] HOSP GEN VALLE HEBRON,SERV BIOQUIM,BARCELONA,SPAIN
[3] HOSP GEN VALLE HEBRON,SERV HEMATOL,BARCELONA,SPAIN
关键词
D O I
10.1128/AAC.40.3.609
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The pharmacokinetics of amphotericin B administered in a conventional 5% dextrose (glucose) (5% D) solution and in a 20% fat emulsion formulation (Intralipid; 20% IL) were compared in 16 patients (mean age, 42 years [range, 18 to 70 years]) who had been hospitalized for hematological malignancies and,vith proven or suspected fungal infections, All of the patients received 50 mg (approximately 1 mg/kg of body weight per day) of amphotericin B daily in random order, either as a 50-ml lipid emulsion (20% IL) (group I) or in 500 mi of 5% D (group II), Five serum samples were taken during the 24 h after drug administration, and the levels of amphotericin B were measured by high-pressure liquid chromatography. Serum amphotericin B concentrations declined rapidly during the first 6 h, and subsequent measurements revealed a slow terminal elimination phase in both groups, The maximum serum amphotericin B concentration was significantly lower when the drug was administered in 20% IL (1.46 +/- 0.61 versus 2.83 +/- 1.17 mu g/ml; P = 0.02), The area under the concentration-time curve from 0 to 24 h was also much lower in group I (17.22 +/- 11.15 versus 28.98 +/- 15.46 mu g . h/ml), The half-life of the distribution phase was approximately three times longer in group 1 (2.92 +/- 2.34 h versus 0.64 +/- 0.24 h; P = 0.011), Conversely, the half-lives of the elimination phase were approximately equal in the two groups (11.44 +/- 5.18 versus 15.23 +/- 5.25 h), The mean residence times were also similar in both groups (19.41 +/- 11.13 versus 19.65 +/- 7.86 h). The clearance and the steady-state volume of distribution of amphotericin B in group I were about twice as great as those in group II (62.97 +/- 35.51 versus 33.01 +/- 14.33 ml/kg/h and 1,043.92 +/- 512.10 versus 562.32 +/- 152.05 ml/kg [P = 0.034], respectively), Finally, the volume of distribution in the central compartment was greater in group I than in group II (618.17 +/- 231.80 versus 328.19 +/- 151.71 ml/kg; P = 0.013), but there were no differences in the volume of distribution in the peripheral compartment (425.75 +/- 352.87 versus 234.14 +/- 75.92 ml/kg), These results suggest that amphotericin B has a different pharmacokinetic profile when it is administered in 20% IL than when it is administered in the standard 5% D form and that the main difference is due to a clear-cut difference in the steady-state volume of distribution, especially that in the central compartment.
引用
收藏
页码:609 / 612
页数:4
相关论文
共 18 条
  • [11] LIPOSOMAL AND LIPID FORMULATIONS OF AMPHOTERICIN-B - CLINICAL PHARMACOKINETICS
    JANKNEGT, R
    DEMARIE, S
    BAKKERWOUDENBERG, IAJM
    CROMMELIN, DJA
    [J]. CLINICAL PHARMACOKINETICS, 1992, 23 (04) : 279 - 291
  • [12] Janoff A.S, 1990, EUR J CLIN MICROBIOL, V9, P146
  • [13] UNUSUAL LIPID STRUCTURES SELECTIVELY REDUCE THE TOXICITY OF AMPHOTERICIN-B
    JANOFF, AS
    BONI, LT
    POPESCU, MC
    MINCHEY, SR
    CULLIS, PR
    MADDEN, TD
    TARASCHI, T
    GRUNER, SM
    SHYAMSUNDER, E
    TATE, MW
    MENDELSOHN, R
    BONNER, D
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (16) : 6122 - 6126
  • [14] COMPARATIVE SAFETY, TOLERANCE, AND PHARMACOKINETICS OF AMPHOTERICIN-B LIPID COMPLEX AND AMPHOTERICIN-B DEOXYCHOLATE IN HEALTHY MALE-VOLUNTEERS
    KAN, VL
    BENNETT, JE
    AMANTEA, MA
    SMOLSKIS, MC
    MCMANUS, E
    GRASELA, DM
    SHERMAN, JW
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1991, 164 (02) : 418 - 421
  • [15] AN EMULSION FORMULATION OF AMPHOTERICIN-B IMPROVES THE THERAPEUTIC INDEX WHEN TREATING SYSTEMIC MURINE CANDIDIASIS
    KIRSH, R
    GOLDSTEIN, R
    TARLOFF, J
    PARRIS, D
    HOOK, J
    HANNA, N
    BUGELSKI, P
    POSTE, G
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1988, 158 (05) : 1065 - 1070
  • [16] REDUCED RENAL TOXICITY AND IMPROVED CLINICAL TOLERANCE OF AMPHOTERICIN-B MIXED WITH INTRALIPID COMPARED WITH CONVENTIONAL AMPHOTERICIN-B IN NEUTROPENIC PATIENTS
    MOREAU, P
    MILPIED, N
    FAYETTE, N
    RAMEE, JF
    HAROUSSEAU, JL
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1992, 30 (04) : 535 - 541
  • [17] SINGLE-DOSE PHARMACOKINETICS AND TOLERANCE OF A CHOLESTERYL SULFATE COMPLEX OF AMPHOTERICIN-B ADMINISTERED TO HEALTHY-VOLUNTEERS
    SANDERS, SW
    BUCHI, KN
    GODDARD, MS
    LANG, JK
    TOLMAN, KG
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (06) : 1029 - 1034
  • [18] EFFECTS OF AMPHOTERICIN-B AND FLUCONAZOLE ON THE EXTRACELLULAR AND INTRACELLULAR GROWTH OF CANDIDA-ALBICANS
    VANETTEN, EWM
    VANDERHEE, NE
    VANKAMPEN, KM
    BAKKERWOUDENBERG, IAJM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (11) : 2275 - 2281